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A b s t r a c t
M o s t cu rren t en zym e im m u n o a ssa ys (E IA s) 
d ifferen tia te  in a d eq u a te ly  b e tw een  types 1 a n d  2 herpes  
s im p lex  v iru s  (H SV ) a n tib o d ies  since  s ig n ifica n t cross­
reactiv ity  exists. We co m p a red  4  Ig G  type-spec ific  E IA s  
u sing  a  W estern  b lo t a ssa y  f o r  reso lu tion  o f  d isc rep a n t 
results. The D ia m ed ix  h a d  sensitiv ities  o f  100%  fo r  
types  1 a n d  2 b u t spec ific ities  o f  o n ly  71%  a n d  61% , 
respectively. T he cross-reac tiv ity  rate w a s  82%  in 
p o s itiv e  sa m p les  tested. F or H S V  types 1 a n d  2, the  
Z eu s  sen sitiv ities  w ere  92%  a n d  98% , respectively; 
spec ific ities  w ere  72%  a n d  79% , respec tively; the cross­
reactiv ity  ra te w a s  54% . F or H S V  types 1 a n d  2, the 
W am pole sen sitiv ities  w ere  98%  a n d  95% , respectively;  
spec ific ities  w ere  68%  a n d  85% , respectively; the cross­
reactiv ity  ra te w a s  47% . F or H S V  types 1 a n d  2, the 
M erid ia n  sen sitiv ities  w ere  98%  a n d  90% , respectively;  
spec ific ities  w ere  96%  a n d  100% , respec tively; no  
cross-reac tiv ity  w a s  fo u n d  b e tw een  p o s itiv e  sam p les  
tested. W hile  the D iam ed ix , Zeus, a n d  W am pole assays  
sh o w e d  g o o d  sensitivity, they la cked  type specificity.
The M erid ia n  E IA  o ffers the h ig h e s t sp ec ific ity  a lo n g  
w ith  n o  o b se rve d  cross-reactivity. This E IA  m a y  be an  
easier, re liab le  a lterna tive  to  W estern  b lo t f o r  the  
d e term in a tio n  o f  H S V  type-spec ific  an tibodies.
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Most herpes simplex infections are not life-threatening, 
except for encephalitis and neonatal infections. Neonatal 
herpes can be a serious disease, often involving the central 
nervous system, with a mortality rate of 70% in untreated 
persons.1 Herpes simplex encephalitis is one of the most 
devastating of all herpes simplex virus (HSV) infections and 
is considered the most common cause of sporadic, fatal 
encephalitis in the United States.2
Many HSV type 2 infections are subclinical and may be 
undiagnosed. Most sexual transmission3,4 and maternal 
transfer to infants5 occurs because people are unaware that 
they have genital herpes. An important factor in the preven­
tion of neonatal herpes, which is most often due to type 2 
infection, is the identification of pregnant women with 
asymptomatic infections. Perhaps even more important may 
be the identification of type 1 or type 2 seronegative pregnant 
women who are near term and who have seropositive part­
ners. Infants born to seronegative mothers acquiring a 
primary case of genital HSV type 2 infection are at a greater 
risk  of acquiring neonatal herpes than infants born to 
seropositive mothers with recurrent genital herpes.5 Primary 
cases late in gestation are particularly dangerous for a 
number of reasons: infants potentially may be exposed to a 
larger viral inoculum; the cervix is much more frequently 
involved, posing a greater risk since transmission usually 
occurs at the time of delivery; and the infant lacks transpla­
centally acquired antibodies.5 In such cases, antiviral inter­
vention and counseling may help prevent neonatal herpes.6,7
Definitive diagnosis of genital herpes is fundamental to 
the management of patients and the development of strategies 
to prevent transmission to partners and neonates.8 Detection 
of herpesvirus-specific antibodies permits diagnosis of an 
infection when virologic methods such as culture, antigen
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detection, and polymerase chain reaction are impractical, too 
costly, or yield negative results.9 Serology is an effective way 
to diagnose subclinical HSV type 2 infections, but most 
available HSV serologic tests are of limited value because 
they cannot accurately discriminate between type 1 and type 
2 HSV antibodies. Because herpesvirus types 1 and 2 share 
many common antigens, there is considerable cross-reac­
tivity among most type 1 and type 2 enzyme immunoassays 
(EIAs) based on whole viral proteins.10 Therefore, deter­
mining whether a positive result in both HSV type 1 and 2 
assays represents cross-reactive antibodies associated with a 
single infection or true dual infection is difficult. Truly type- 
specific serologic assays would permit accurate identification 
of asymptomatic HSV type 2 infection in patients with or 
without preexisting antibodies to type 1 HSV. Such tests 
could provide useful information in the diagnosis of subclin- 
ical or undiagnosed HSV type 2 infections, as well as aid in 
the prevention of maternal transfer of HSV to the neonate.
Several type-specific antibody tests are available that are 
based on Western blot (WB) analysis and purified type- 
specific glycoprotein G from types 1 and 2 HSV. WB 
analysis has the ability to distinguish between types 1 and 2 
antibody and is considered the traditional “gold standard” for 
differentiating between type 1 and type 2 antibodies. Owing 
to its cumbersome nature and the lack of a readily available 
antigen source, WB analysis is not a practical option for 
most clinical laboratories. Recently, type-specific purified 
glycoproteins have been used to develop reliable immunoas­
says to detect antibodies to HSV. The HSV type 1 glycopro­
tein G (gG-1) and HSV type 2 glycoprotein (gG-2) show 
little sequence homology. The common cross-reactive 
sequences are found primarily in the leader sequence, which 
is lost during processing of the proteins after translation, and 
in the membrane anchor region, which has limited immuno- 
genicity owing to its sequestration in the infected cell 
membrane.8,11,12 Several commercial assays based on these 
proteins are available.
M aterials and Methods
Samples
In these studies, serum samples from 158 patients 
submitted to our reference laboratory for HSV IgG EIA 
testing were examined. Specimens were stored at -20° C 
before testing and at 2°C to 8°C between individual assays. 
All samples were free of substantial lipemia, hemolysis, and 
bacterial contamination.
Enzyme Immunoassays
We evaluated 4 commercially available type-specific 
EIAs using WB analysis, the accepted gold standard, for
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resolution of discrepant results. Three of the assays (from 
Diamedix, Miami, FL; Wampole Laboratories, Cranbury, NJ; 
and Zeus Scientific, Raritan, NJ) are based on inactivated 
viral particles, whereas the assay from Meridian Diagnostics 
(formerly Gull Laboratories), Cincinnati, OH, is based on 
affinity-purified glycoprotein types 1 and 2 HSV antigens (F 
strain). All EIAs were labeled “For in vitro diagnostic use” 
according to US Food and Drug Administration regulations. 
Any sample results that were not in total agreement, either 
all positive or negative by the 4 EIAs, were considered 
discrepant. WB analysis was performed on these samples to 
resolve the discrepancies. The discrepant samples were 
coded and sent blinded to Meridian Diagnostics, which 
performed and interpreted the WB results. All EIAs were 
performed and results interpreted in accordance with the 
manufacturers’ protocols. Results for the EIAs were deter­
mined by dividing the spectrophotometric absorbance of the 
patient sample by the absorbance of a cutoff or calibrator 
control. This ratio was then used to create an index value 
from which a semiquantitative result was obtained. For the 
present study, the qualitative positive, negative, or equivocal 
result was used for comparison calculations of sensitivity 
and specificity. Sensitivity was determined as follows: 
number of true-positive results (as resolved by WB analysis) 
divided by the sum of the number of true-positive results 
plus the number of false-negative results, for each individual 
assay. The number of true-negative results divided by the 
sum of the number of true-negative results plus the number 
of false-positive results was used to calculate specificity.
WB Analysis
For WB analysis, a type-specific antibody assay 
described in the literature was used.13 Briefly, antigen was 
extracted from HSV type 1 or HSV type 2 infected human 
diploid fibroblasts, electrophoresed into polyacrylamide 
gradient gels, and electrotransferred onto nitrocellulose 
membranes. Patient samples and controls were run both 
unadsorbed and adsorbed. For adsorption, samples first were 
incubated with type 1 or type 2 antigens coupled with 
sepharose. Three lanes then were run for each sample: an 
unadsorbed lane, a type 1 adsorbed lane, and a type 2 
adsorbed lane. Each sample was run on a type 1 and a type 2 
membrane strip for a total of 6 lanes per sample. Results 
were interpreted as follows: seronegative, no bands or weak 
bands to nonviral proteins as determined by comparison with 
binding patterns on strips reacted with known positive serum 
samples; type 1 positive, predominance of binding to the type 
1 strip, or binding present on the 2 strips with an absence of 
reactivity with the gG-2 bands on the type 2 strip; type 2 
positive, predominance of binding to the type 2 strip along 
with reactivity to gG-2; type 1 and type 2 positive, full anti­
body profile on type 1 and type 2 strips, including reactivity
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with gG-2; indeterminate, atypical reactivity on either type 1 
or type 2 strip or equivalent reactivity on each strip without a 
clear gG-2 band on the type 2 strip.
Results
The results of the samples in total agreement were 
combined with the results of the WB analysis-resolved 
samples to calculate sensitivity and specificity. Additional 
sensitivity studies were conducted by examining the vari­
ability of antibody titer of the 4 EIAs by diluting seropositive 
samples. Cross-reactivity was defined by the samples posi­
tive for a single type only by WB analysis and positive for 
both types by the comparative EIA.
Of the 158 serum samples tested by the 4 EIA methods, 
total agreement of type 1 and type 2 results were seen in only 
78 (49.4%) of the samples ITable 11. For the 80 discrepant 
samples, the interpretation for the WB analysis was consid­
ered the resolved or correct result and used to calculate the 
sensitivity and specificity of each EIA. Results from 2 
samples that were indeterminate by WB analysis and the 
equivocal EIA results were not included in the calculations 
of sensitivity and specificity. There seemed to be little or no
correlation of the 19 equivocal results among the 4 EIAs. 
Within the individual assays, there was no correlation 
between type 1 and type 2 equivocal results, as none of the 
type 1 equivocal results were equivocal for type 2, and vice 
versa. When comparing the equivocal results for the 4 EIAs 
across the board, there were only 2 cases (of 19 total) in 
which more than 1 assay reported an equivocal result for the 
same sample. In the first case, the Meridian and Wampole 
assays both reported equivocal results for type 1 for the same 
sample. This sample had a positive result by the Diamedix 
assay, a negative result by the Zeus assay, and was positive 
by WB analysis. In the second case, both Wampole and Zeus 
gave equivocal results for type 2 for a sample that was posi­
tive by the Diamedix assay and negative by the Meridian 
assay. The type 2 WB analysis result for this sample was 
negative. Of the 2 indeterminate results by WB analysis, the 
Diamedix, Wampole, and Zeus assays reported positive 
results for types 1 and 2. The Meridian assay reported one of 
these samples as positive for type 1 and negative for type 2 
and the other sample as negative for type 1 and positive for 
type 2.
The 4 EIA methods all showed good reproducibility. By 
using the semiquantitative index value, the intra-assay coeffi­
cient of variation was less 7% for all 4 assays, while
I Table 1I
Herpes Simplex Virus IgG Antibody Type Comparison of 4 Enzyme Immunoassays With Western Blot Analysis-Resolved Results 
for 158 Patient Serum Samples*
No. of Samples With Western Blot Analysis-Resolved Results
Positive Negative Indeterminate
Diamedix
Type 1 result Positive 8 6 20 2
Negative 0 50 0
Type 2 result Positive 60 37 2
Negative 0 59 0
Type 1 result Positive 77 19 2
Negative 7 49 0
Equivocal 2 2 0
Type 2 result Positive 59 19 2
Negative 1 73 0
Equivocal 0 4 0
Wampole
Type 1 result Positive 83 22 2
Negative 2 46 0
Equivocal 1 2 0
Type 2 result Positive 57 14 2
Negative 3 79 0
Equivocal 0 3 0
Meridian
Type 1 result Positive 82 3 1
Negative 2 66 1
Equivocal 2 1 0
Type 2 result Positive 53 0 1
Negative 6 95 1
Equivocal 1 1 0
* Indeterminate and equivocal results not included in calculations of sensitivity and specificity. Diamedix, Miami, FL; Zeus Scientific, Raritan, NJ; Wampole Laboratories, Cran- 
bury, NJ; Meridian Diagnostics (formerly Gull Laboratories), Cincinnati, OH.
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interassay coefficients of variation were all less than 15%. 
These results were generated by running samples with high, 
medium, and low positive results in replicates of 5 on 3 sepa­
rate days.
The Diamedix EIA showed high sensitivity, identifying 
86 (100%) of 86 HSV type 1 positive samples and 60 (100%) 
of 60 HSV type 2 positive samples. It also was the least 
specific, correctly identifying only 50 (71%) of 70 type 1 
negative samples and 59 (61%) of 96 type 2 negative samples. 
The Diamedix assay does not include an equivocal range in 
the result interpretation. Fifty-six of 68 samples were positive 
for both types by EIA but positive for only 1 type by the WB 
analysis-resolved results (47 type 1, 21 type 2) for a cross­
reactivity rate of 82%. The cross-reactivity rate was lower 
among the samples that were positive for type 1 and negative 
for type 2 (76% [36/47]) than among samples that were nega­
tive for type 1 and positive for type 2 (95% [20/21]).
Of the samples identified as positive by WB analysis, 
the Zeus EIA correctly identified 77 (92%) of 84 samples as 
positive for type 1 and 59 (98%) of 60 samples as positive 
for type 2. Forty-nine of 68 samples negative for type 1 by 
WB analysis were identified correctly as such, yielding a 
specificity of 72%, and 73 of 92 samples negative for type 2 
were identified correctly, for a specificity of 79%. The Zeus 
assay for type 1 had 4 equivocal results (2 positive and 2 
negative by WB analysis). The assay for type 2 also had 4 
equivocal results (all negative by WB analysis). Cross-reac­
tivity of the Zeus EIA was seen in 37 (54%) of 68 samples 
positive for only 1 type by WB analysis. The cross-reactivity 
rate was lower for the samples that were positive only for 
type 1 (40% [19/47]) than for the samples that were positive 
only for type 2 (86% [18/21]).
The Wampole EIA correctly identified 83 (98%) of 85 
samples positive for type 1 positives and 57 (95%) of 60 
samples positive for type 2. For type 1 antibodies, a speci­
ficity of 68% (46/68) was calculated, while for type 2, speci­
ficity was 85% (79 of 93 samples negative for type 2 were 
identified correctly). The assay reported 3 equivocal results 
(1 positive, 2 negative by WB analysis) for type 1 and 3 
equivocal results for type 2 (all negative by WB analysis). 
Thirty-two of 68 samples were positive for both types by EIA 
but positive for only 1 type by the WB analysis-resolved 
results, for a cross-reactivity rate of 47%. Like the Diamedix 
and Zeus assays, the cross-reactivity rate was lower among 
the samples that were positive for type 1 and negative for 
type 2 (28% [13/47]) than among samples that were negative 
for type 1 and positive for type 2 (90%) [19/21]).
For the Meridian assay, 82 of 84 samples positive for 
type 1 were identified correctly, resulting in a sensitivity of 
98%. Fifty-three of 59 samples were identified correctly as 
positive for type 2, which yielded a sensitivity of 90%. The 
Meridian EIA had a specificity of 96% (66 of 69 correctly
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identified as negative) for type 1, while all 95 samples nega­
tive for type 2 (by WB analysis) were identified correctly by 
EIA for a specificity of 100%. Cross-reactivity was not seen 
in any of the 68 samples positive for only 1 antibody type by 
WB analysis.
Additional sensitivity studies were done with the EIAs 
by serially diluting 10 positive samples. The reciprocals of 
the highest dilutions that still gave a positive result when 
compared with the assay calibrator were used as the titer 
values IFigure 11. Sample 29 was negative by WB analysis, 
as well as by the Diamedix, Wampole, and Zeus assays. 
Sample 7 was positive for type 1 and negative for type 2, 
while samples 27 and 34 were negative for type 1 and posi­
tive for type 2 by WB analysis.
Discussion
As the literature suggests, our study confirms the neces­
sity of using specific antigenic markers, such as purified
A
■  Meridian
29 37 42 54 132 138 145 7 27 34
Sam ple
■  Meridian
29 37 42 54 132 138 145 7 27 34
Sam ple
IFigure 1I Comparison of titer values of 4 enzyme immuno­
assays. A, Herpes simplex virus type 1. B, Herpes simplex 
virus type 2. Meridian Diagnostics (formerly Gull Laborato­
ries), Cincinnati, OH; Diamedix, Miami, FL; Wampole Labora­
tories, Cranbury, NJ; Zeus Scientific, Raritan, NJ.
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glycoproteins, for accurate type-specific determination of 
HSV antibodies. While the 3 assays incorporating nonspe­
cific whole viral proteins, Diamedix, Zeus, and Wampole, all 
showed good sensitivity for detecting HSV antibodies, 
ranging from 92% to 100%, they cannot differentiate 
adequately between types 1 and 2. This was evident in the 
low specificities observed for these assays, which ranged 
greatly, with Wampole having the highest (85%) for type 2 
and Diamedix the lowest (61%) for type 2. In contrast, the 
purified glycoproteins used in the Meridian assay had speci­
ficities of 96% and 100% for types 1 and 2, respectively. Our 
calculated sensitivity of 90% for the Meridian type 2 assay 
was lower than the 98% in previously published data.14
There seemed to be little or no correlation among the 4 
EIAs for the 19 equivocal results. There was no correlation 
between type 1 and type 2 equivocal results, as none of the 
type 1 equivocal results were equivocal for type 2 and vice 
versa. When comparing the equivocal results of the 4 EIAs 
across the board, there were only 2 cases (of 19 total) in 
which more than 1 assay gave an equivocal result for the 
same sample. In the first case, the Meridian and Wampole 
assays both reported equivocal results for type 1 on the same 
sample. This sample had a positive result by Diamedix and a 
negative result by Zeus and was positive by WB analysis. In 
the second case, the Wampole and Zeus assays gave equiv­
ocal results for type 2 on a sample that was positive by the 
Diamedix assay and negative by the Meridian assay. The 
type 2 WB analysis result for this sample was negative. Of 
the 2 indeterminate results by WB analysis, the Diamedix, 
Wampole, and Zeus assays reported positive results for both 
types 1 and 2. The Meridian assay reported one of these 
samples as positive for type 1 and negative for type 2 and the 
other as negative for type 1 and positive for type 2.
When comparing antibody titer levels of positive 
samples on the 4 EIAs, the Diamedix assay was consistently 
more sensitive (Figure 1). Of the 9 positive samples exam­
ined, the Diamedix assay always had the highest titer for 
both type 1 and 2 antibodies. In 16 of 18 cases, the Wampole 
assay was at least 1 titer higher than the Zeus assay, with the 
remaining 2 assays showing equivalent titers. The Meridian 
assay was more variable, having sometimes lower and some­
times higher titers than the Zeus and Wampole assays.
Cross-reactivity was clearly evident with the Diamedix, 
Zeus, and Wampole whole viral antigen-based assays, with 
types 1 and 2 combined rates ranging from a low of 47% for 
the Wampole test to a high of 82% for the Diamedix assay. 
These assays also were alike in that the cross-reactivity rate 
was higher in samples that were negative for type 1 and posi­
tive for type 2 than in samples that were positive for type 1 
and negative for type 2. In contrast, the Meridian assay 
showed no cross-reactivity in the 65 samples that were deter­
mined by WB analysis to be positive for only 1 antibody type.
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The results from our study compare favorably with eval­
uations of other EIAs based on the HSV type-specific puri­
fied G glycoproteins. An evaluation by Prince et al15 of the 
MRL Diagnostics (Cypress, CA) immunoassay showed 
sensitivities for HSV type 1 and 2 antibodies of 100% and 
specificities of greater than 95%. These results are compa­
rable to the results for the Meridian assay, which demon­
strated slightly lower sensitivities (98% for type 1 and 90% 
for type 2) but slightly higher specificities (96% and 100% 
for types 1 and 2 antibodies, respectively).
The main difference between the 2 assays is that the 
MRL EIA uses recombinant gG-1 and gG-2 antigens, while 
the Meridian EIA uses native affinity-purified gG-1 and gG-
2. Although studies have shown these type-specific tests to 
be superior to assays based on whole antigen preparations, 
there are limitations to the HSV glycoprotein G-based 
assays. Recombinant glycoprotein G proteins usually are 
derived from bacteria or baculovirus expression vectors and 
may not detect all the antibodies elicited in humans by expo­
sure to native glycoprotein G. Recombinant antigens also 
may lack epitopes that depend on glycosylation mechanisms 
of mammalian cells.8 Affinity purified glycoprotein G, 
therefore, is more likely to provide the complete comple­
ment of native epitopes. As with any test based on anti­
bodies to 1 protein, not all people may produce an antibody 
response to the specific protein. In addition, glycoprotein G 
is not an essential protein for HSV viral replication, and 
infections may occur with glycoprotein G-deficient virus. 
As a result, 5% to 10% of patients may lack detectable anti­
body to glycoprotein G after infection.8 Patients with early 
HSV infection also may have negative test results for IgG 
antibodies, since the IgG response to the glycoprotein G 
antigen arises relatively late. Studies have shown that anti­
body to glycoprotein G first appears 2 to 3 months after 
initial infection in 60% to 70% of patients, while the 
remaining patients may require up to 6 months to serocon- 
vert to glycoprotein G.8
Even with these limitations, EIA-based tests offer many 
advantages. Most laboratories are well equipped with 
personnel and instrumentation to run these types of tests. It is 
a method that is recognized and used commonly and is less 
expensive and laborious than WB analysis. Because results 
are read by a spectrophotometer, the subjectivity of WB 
analysis band interpretation is not a factor.
The use of purified gG-1 and gG-2 from HSV types 1 
and 2, respectively, as specific antigens has permitted accu­
rate type-specific discrimination of HSV antibodies. The 
application of these truly type-specific markers in a commer­
cially available microtiter plate EIA format provides a more 
practical and less time-consuming alternative to WB 
analysis, especially for testing large volumes of samples.
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